KFSHRC Advances Robotic Surgery with a Successful Ivor Lewis Esophagectomy
The procedure was led by Dr. Khalid Aldaghri, Consultant in bariatric, upper gastrointestinal, and robotic surgery at KFSHRC. Utilizing the Ivor Lewis technique, a complex and technically demanding procedure involving two phases. The abdominal phase involved stomach mobilization and creation of a gastric conduit. This was followed by the thoracic phase, in which the diseased esophagus was resected and the conduit is robotically connected within the chest.
Precision in the robotic system enabled surgeons to reach deep anatomical areas without large incisions, enhancing safety, reducing risks, and improving outcomes in one of the most complex cancer surgeries.
Close collaboration among surgical, anesthesia, nursing, and technical teams was key to the procedure's success. All teams worked synchronously across every stage, from pre-op planning to post-op recovery. This approach reflects KFSHRC's multidisciplinary model of care, designed to improve patient outcomes and boost clinical efficiency.
With its advanced features, the robotic surgery significantly enhanced the safety and accuracy of the esophagectomy by offering three-dimensional high-definition visualization, stable instrument control, and superior access within confined anatomical spaces. These capabilities enabled more precise dissection, better preservation of surrounding structures such as nerves and vessels and reduced intraoperative risks. The technology also made it physically easier for the surgeon to operate over an extended period.
As a medical milestone, the success of this procedure opens the door for broader applications of robotic surgery at KFSHRC. It enables more patients to benefit from advanced surgical techniques and reinforces the institution's commitment to clinical innovation, safety, and effective alternatives to traditional surgical approaches.
It is noteworthy that KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world's top 250 Academic Medical Centres for the third consecutive year and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. For more information, visit
www.kfshrc.edu.sa
or contact our media team at
mediacoverage@kfshrc.edu.sa
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/45f95dc0-9a6c-4e12-a353-2c329acd9c9b
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Erectile Dysfunction Devices Market Set to Surge at a CAGR of ~8% by 2032 with Rising Global Demand and Technological Advancements
The demand for erectile dysfunction devices is largely fueled by the growing incidence of ED, especially among men with chronic health conditions like cardiovascular disease, diabetes, and hypertension. While ED can affect men across all age groups, it is more commonly seen in older adults who often have associated health concerns such as prostate cancer, anxiety, and depression. Furthermore, the expanding elderly male population, combined with higher rates of obesity and sedentary behaviors like smoking and physical inactivity, are significant contributor to the market's expansion. New York, USA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Erectile Dysfunction Devices Market Set to Surge at a CAGR of ~8% by 2032 with Rising Global Demand and Technological Advancements | DelveInsight The demand for erectile dysfunction devices is largely fueled by the growing incidence of ED, especially among men with chronic health conditions like cardiovascular disease, diabetes, and hypertension. While ED can affect men across all age groups, it is more commonly seen in older adults who often have associated health concerns such as prostate cancer, anxiety, and depression. Furthermore, the expanding elderly male population, combined with higher rates of obesity and sedentary behaviors like smoking and physical inactivity, are significant contributor to the market's expansion. DelveInsight's Erectile Dysfunction Devices Market Insights report provides the current and forecast market analysis, individual leading erectile dysfunction devices companies' market shares, challenges, erectile dysfunction devices market drivers, barriers, trends, and key erectile dysfunction devices companies such as Coloplast Group, Zimmer Aesthetics, Augusta Medical Systems, Medispec, MTS Medical, Boston Scientific Corporation, NOVAmedtek, Promedon GmbH, and others in the market. Erectile Dysfunction Devices Overview Erectile dysfunction devices play a crucial role in the management of erectile dysfunction, a condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. These devices are particularly valuable for men who cannot take or do not respond to oral pharmacological treatments. Common types of ED devices include vacuum erection devices (VEDs), penile implants (inflatable or malleable), and constriction rings. VEDs work by creating a vacuum around the penis to draw blood into it, while penile implants offer a more permanent solution through surgically inserted devices that mimic the natural erection process. These options provide men with greater control over their sexual function and can significantly improve the quality of life and Dysfunction Devices Regional Market Insights North America dominated the erectile dysfunction devices market in 2024, owing to several critical factors. This leadership is primarily driven by the increasing incidence of erectile dysfunction and rising awareness about the condition among the regional population. Contributing to this trend is the growing number of individuals affected by prostate cancer, hypertension, and diabetes—key risk factors for erectile dysfunction. Additionally, major industry players in the region are prioritizing technological progress and product development. For instance, in January 2025, Comphya SA, an innovative medtech company, received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to commence clinical trials for CaverSTIM, the first implantable neuromodulator designed to treat erectile dysfunction. These advancements are expected to drive significant growth in the market by providing new treatment options for affected individuals. As a result, the convergence of rising erectile dysfunction cases, a high burden of contributing health conditions, and ongoing innovation in device technology is projected to fuel substantial market growth in North America between 2025 and 2032. To know more about why North America is leading the market growth in the erectile dysfunction devices market, get a snapshot of the Erectile Dysfunction Devices Market Outlook Recent Developments in the Erectile Dysfunction Devices Market In January 2025, Comphya SA, a pioneering medical technology company, announced that the FDA granted Investigational Device Exemption (IDE) approval to initiate clinical trials for CaverSTIM, the first implantable neuromodulator developed to treat erectile dysfunction. In June 2024, Ohh-Med Medical Ltd. launched VerticaPlus with a cloud-based mobile app. Vertica is a pioneering medical device designed to enhance erection quality over time by targeting the Tunica Albuginea in the penis, thereby reducing leakage and outflow. This innovative approach optimizes the natural erectile mechanism without relying on medication, allowing for complete spontaneity in intimate relations and eliminating associated side effects. To read more about the latest highlights related to the erectile dysfunction devices market, get a snapshot of the key highlights entailed in the Erectile Dysfunction Devices Key Players in the Erectile Dysfunction Devices Market The erectile dysfunction devices market is driven by several key players that focus on technological innovation, product development, and strategic partnerships to expand their market share. Prominent companies such as Coloplast Group, Zimmer Aesthetics, Augusta Medical Systems, Medispec, MTS Medical, Boston Scientific Corporation, NOVAmedtek, Promedon GmbH, Global Life Technologies LLC, Zephyr Surgical Implants, Owen Mumford, Vacurect, T.E. Inc., SILIMED, STORZ MEDICAL AG, Rigicon, Inc., TIMM Medical, Alma Lasers, Comphya SA, Ohh-Med Medical Ltd., and others are at the forefront of the industry. These firms offer a range of medical devices, including vacuum erection devices (VEDs), penile implants, and constriction rings, catering to diverse patient needs. Their emphasis on clinically effective solutions, robust research and development pipelines, and global distribution networks has positioned them as leaders in the growing erectile dysfunction devices market. Which MedTech key players in the erectile dysfunction devices market are set to emerge as the trendsetter explore @ Top Erectile Dysfunction Devices Companies Erectile Dysfunction Devices Market Key Factor Analysis Erectile Dysfunction Devices Market Drivers The erectile dysfunction devices market is primarily driven by the growing prevalence of erectile dysfunction worldwide. This rise is closely linked to an increase in the number of risk factors, such as diabetes, cardiovascular diseases, obesity, and lifestyle-related conditions that contribute to the onset of erectile dysfunction. Additionally, the expanding geriatric male population, which is more susceptible to such conditions due to age-related physiological changes, is further propelling the demand for effective treatment solutions, including medical devices designed to manage erectile dysfunction. Erectile Dysfunction Devices Market Restraints and Challenges One of the major restraints in the erectile dysfunction devices market is the high cost of advanced devices, which limits accessibility for a large segment of the patient population, particularly in developing regions. Additionally, the complexity of these devices and the potential risk of malfunction pose significant challenges, often leading to patient hesitation and reduced adoption rates. These factors collectively hinder the widespread use and acceptance of erectile dysfunction devices despite their clinical benefits. Erectile Dysfunction Devices Market Opportunities The erectile dysfunction devices market presents significant growth opportunities driven by the integration of advanced technologies, such as robotic implantation and other innovative approaches. These advancements are enhancing the precision, safety, and effectiveness of erectile dysfunction treatments, leading to improved patient outcomes and satisfaction. As healthcare systems increasingly adopt minimally invasive and tech-enabled solutions, the demand for technologically sophisticated erectile dysfunction devices is expected to rise, creating a favorable environment for market expansion. Get a sneak peek at the erectile dysfunction devices market dynamics @ Global Erectile Dysfunction Devices Market Report Report Metrics Details Coverage Global Study Period 2022–2032 Erectile Dysfunction Devices Market CAGR ~8% Erectile Dysfunction Devices Market Size by 2032 USD 3 Billion Key Erectile Dysfunction Devices Companies Coloplast Group, Zimmer Aesthetics, Augusta Medical Systems, Medispec, MTS Medical, Boston Scientific Corporation, NOVAmedtek, Promedon GmbH, Global Life Technologies LLC, Zephyr Surgical Implants, Owen Mumford, Vacurect, T.E. Inc., SILIMED, STORZ MEDICAL AG, Rigicon, Inc., TIMM Medical, Alma Lasers, Comphya SA, Ohh-Med Medical Ltd., and others Erectile Dysfunction Devices Market Assessment Erectile Dysfunction Devices Market Segmentation Erectile Dysfunction Devices Market Segmentation By Product: Penile Implants, Shockwave Therapy Devices, Vacuum Therapy Devices, and Others Erectile Dysfunction Devices Market Segmentation By Approach: Invasive and Non-Invasive Erectile Dysfunction Devices Market Segmentation By End User: Hospitals & Clinics, Ambulatory Surgical Centers, and Others Erectile Dysfunction Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Interested in knowing the erectile dysfunction devices market by 2032? Click to get a snapshot of the Erectile Dysfunction Devices Market Analysis Table of Contents 1 Erectile Dysfunction Devices Market Report Introduction 2 Erectile Dysfunction Devices Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Erectile Dysfunction Devices Market Key Factors Analysis 6 Erectile Dysfunction Devices Market Porter's Five Forces Analysis 7 Erectile Dysfunction Devices Market Layout 8 Erectile Dysfunction Devices Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Related Reports Erectile Dysfunction Market Erectile Dysfunction Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key erectile dysfunction companies, including Vigonvita Life Sciences, Futura Medical Developments, Initiator Pharma, Pharmicell Co., Ltd., BioIntegrate, Biozeus Biopharmaceutical, Can-Fite Biopharma, Fabre-Kramer Pharmaceuticals, Humanetics Pharmaceuticals, Hemostemix Inc., Ilgen Bio, Aquestive Therapeutics, MicroCures, Dicot AB, CURE Pharmaceutical, IX BIOPHARMA, Exopharm, Oncotelic Therapeutics, Blue Cell Therapeutics, S1 Biopharma, among others. Erectile Dysfunction Pipeline Erectile Dysfunction Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key erectile dysfunction companies, including Vigonvita Life Sciences, Futura Medical Developments, Initiator Pharma, Pharmicell Co., Ltd., BioIntegrate, Biozeus Biopharmaceutical, Can-Fite Biopharma, Fabre-Kramer Pharmaceuticals, Humanetics Pharmaceuticals, Hemostemix Inc., Ilgen Bio, Aquestive Therapeutics, MicroCures, Dicot AB, CURE Pharmaceutical, IX BIOPHARMA, Exopharm, Oncotelic Therapeutics, Blue Cell Therapeutics, S1 Biopharma, among others. Prostate Cancer Market Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others. Prostate Cancer Pipeline Prostate Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key prostate cancer companies, including Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, among others. Prostate Cancer Diagnostics Market Prostate Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer diagnostics companies, including F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Abbott., MDx Health, Siemens Healthcare, OPKO Health, Inc., Genomic Health, Inc., Agilent Technologies, Inc., BD., BIOCEPT, INC., Proteomedix, A3P Biomedical AB, GE HealthCare., Soteria Medical BV, Bio-Techne., Indica Labs, Inc., miR Scientific, MINOMIC®, ACON Laboratories, Inc., Hologic, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us Shruti Thakur info@ +14699457679 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
5 hours ago
- Business Upturn
Mellow Sleep Redefines Comfort with a Revolutionary New Cloud Pillow
Dover, Aug. 12, 2025 (GLOBE NEWSWIRE) — DOVER, DE – August 11, 2025 – Mellow Sleep, a leader in sleep ergonomics and material science, today announced the launch of a revolutionary new cloud pillow designed to permanently solve the universal problem of restless, unfulfilling sleep. This launch marks a new era for sleep wellness, moving beyond one-size-fits-all solutions to offer a truly personalized and restorative experience. The frustrating, nightly search for a pillow that is 'just right' is finally over. Millions of people struggle with pillows that are too firm, too soft, too high, or too low, leading to neck pain, shoulder stiffness, and persistent fatigue. This nightly battle for comfort often involves folding, bunching, or stacking pillows in a desperate attempt to find support. Mellow Sleep addresses this issue at its core with a groundbreaking cloud pillow that intelligently adapts to the sleeper. This innovative pillow solves sleep discomfort through its proprietary 3-zone contour design. Each zone is meticulously engineered for a distinct biomechanical purpose. The central contour cradles the head with gentle, pressure-relieving support, while the raised outer edges are optimized for side sleepers, filling the gap between the shoulder and neck. The third zone provides a specialized cervical ramp that delivers a targeted lift, ensuring the spine maintains a natural and healthy alignment throughout the night. This integrated system prevents the awkward angles that lead to morning aches and pains. 'Our goal was to create the perfect cloud pillow by listening to the real-world frustrations of sleepers,' said Jay Yue, founder of Mellow Sleep. 'People are tired of compromising. They shouldn't have to choose between a soft feel and firm support. We spent years researching materials and ergonomics to find a way to deliver both. The result is our new CloudAlign™ Pillow, a product we believe sets a new industry standard for what a pillow can and should do for your well-being. It's more than just a place to rest your head; it's an investment in your health.' At the heart of this exceptional Mellow Sleep cloud pillow is the CloudSoft Core™, a proprietary shape-retaining memory foam. Unlike conventional foams that can be slow to respond or lose shape, the CloudSoft Core™ offers dynamic, flexible support that adapts instantly to every micro-movement. This ensures consistent comfort and alignment, whether you are a back, side, or combination sleeper. The exterior is just as thoughtfully designed. The pillow is encased in a removable, OEKO-TEX® Certified cover. This certification guarantees the fabric is free from harmful chemicals, making it hypoallergenic, breathable, and exceptionally gentle on the skin. Further enhancing its superior adaptability, the pillow features a SwitchFit™ design. This innovative feature gives users dual-height support, allowing them to simply flip the pillow to choose between a lower and a higher profile to perfectly match their body frame and sleep preference. For lasting hygiene, all materials are fast-drying and easily washable. This new Mellow Sleep cloud pillow from Mellow Sleep is now available for purchase directly from the company's website: offering an end to compromise and a new beginning for deep, restorative sleep. About Mellow Sleep: Mellow Sleep is a forward-thinking company dedicated to advancing human well-being through the science of sleep. By focusing on biomechanics, certified non-toxic materials, and user-centric design, Mellow Sleep creates innovative products that provide tangible improvements to sleep health. Their mission is to engineer a better night's sleep for a better life. Media Contact: [email protected] ### For more information about Mellow LLC, contact the company here: Mellow LLCJay Yue9293555134 [email protected] 8 The Green, Dover, DE 19901
Yahoo
8 hours ago
- Yahoo
In Vitro Diagnostics Market Size to Exceed USD 132.18 Bn by 2034
According to Precedence Research, the global in vitro diagnostics (IVD) market size is expected to exceed USD 132.07 billion by 2034, increasing from USD 104.01 billion in 2025, with a CAGR of 2.30% between 2025 and 2034. Growth is fueled by rising chronic disease prevalence, demand for early detection, and rapid adoption of advanced molecular testing technologies. Ottawa, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The worldwide in vitro diagnostics market size accounted for USD 102.05 billion in 2024, and is predicted to grow from USD 104.01 billion in 2025 to approximately USD 132.07 billion by 2034. The growing awareness about the early detection of diseases and the growing prevalence of chronic diseases drive market growth. Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for Before You Buy – Get the Sample Report@ In Vitro Diagnostics Industry – Strategic Insights In terms of revenue, the in vitro diagnostics market has been calculated at USD 104.01 billion in 2025. It is anticipated to reach over USD 132.07 billion by 2034. North America captured a 42% revenue share of the global market in 2024. Asia Pacific is expected to grow at a significant CAGR between 2025 and 2034. By product, the reagents segment held the major market share of 66.07% in 2024. By product, the instruments segment is expanding at a solid CAGR from 2025 to 2034. By test location, the point-of-care segment held a significant share in 2024. By test location, the home care segment is anticipated to witness considerable growth from 2025 to 2034 By technology, the molecular diagnostics segment contributed the largest market share of 33.06% in 2024. By technology, the immunoassay segment is projected to grow at a considerable CAGR from 2025 to 2034. By application, the infectious disease segment accounted for the biggest market share of 52.53% in 2024. By application, the oncology segment is growing at a notable CAGR between 2025 and 2034. By end user, the hospital segment held the largest market share of 37.89% in 2024. In Vitro Diagnostics Market Revenue (USD Million) By Product Type 2022-2024 Product 2022 2023 2024 Instruments 28,950.5 26,909.55 25,379.75 Reagents 75,883.9 70,996.28 67,404.76 Services 10,654.3 9,861.36 9,264.58 In Vitro Diagnostics Market Revenue (USD Million) By Technology 2022-2024 Technology 2022 2023 2024 Immunoassay 34,688.2 32,433.72 30,774.22 Hematology 6,827.4 6,345.41 5,984.69 Clinical Chemistry 20,236.7 18,978.14 18,061.02 Molecular Diagnosis 38,255.7 35,662.26 33,736.25 Coagulation 4,680.5 4,328.27 4,061.72 Microbiology 6,384.9 5,916.29 5,563.15 Others 4,415.3 4,103.12 3,868.03 In Vitro Diagnostics Market Revenue (USD Million) By Application 2022-2024 Application 2022 2023 2024 Infectious Diseases 61,149.9 56,833.27 53,602.44 Diabetes 9,146.6 8,475.36 7,969.48 Oncology 8,727.7 8,323.38 8,055.14 Cardiology 9,104.3 8,538.03 8,125.43 Nephrology 6,633.3 6,127.88 5,744.71 Autoimmune Diseases 5,350.6 4,987.83 4,718.45 Drug Testing 3,986.6 3,757.30 3,593.52 Others 11,389.6 10,724.14 10,239.92 Available for Instant Download – Order This Premium Market Study Today@ In Vitro Diagnostics Market Overview In vitro diagnostics (IVD) are tests conducted on samples retrieved from human bodily tissues and fluids. IVD performs on biological samples like tissue, blood, urine, and others, and tests are performed in the laboratory. Tests help to diagnose various infections, diseases, & other health issues, and monitor patient health. IVD helps in the early detection of diseases, avoids the spreading of diseases, and enhances patient care. The common IVD tests are COVID-19, HIV tests, pregnancy tests, blood glucose monitoring, and many more. Factors like a rise in personalised medicines, increasing awareness about the early detection of diseases, growing cardiovascular diseases, and technological advancements in IVD contribute to the in vitro diagnostics market. Top Types of IVD Technologies in 2025: Technology Working Principle Uses ELISA Capturing the antigen-antibody reaction Autoimmune disorder HIV Lyme Disease NGS DNA fragmentation and parallel sequencing Cancer Genetic disorders Infectious diseases CLIA The binding antibody and the corresponding antigenChemiluminescence reactions Hormone imbalances Tumor detection Diabetes Hypertension PCR/RT-PCR Amplification of DNA & RNA Genetic disorder Infectious diseases Flow Cytometry Laser-based techniques for the analysis of cells Blood disorders Immune system problems Myelodysplastic syndromes Lateral Flow Sample amplification and target binding Pregnancy Respiratory infections Mosquito-borne diseases Sexually transmitted infections ➤ In Vitro Diagnostics Market Major Trends: Advanced Lateral Flow Tests (LFTs) Beyond COVID-19Evolved LFTs are now capable of detecting a wide array of substances—from vitamin D and iron to stroke markers—using novel samples like fingerprint sweat or pet vomit. Their versatility is rapidly expanding across healthcare, environmental, and even animal diagnostics. Integrated Point-of-Care and At-Home Nutritional DiagnosticsInnovations like smartphone-compatible devices (e.g., Cornell's NutriPhone) can measure iron, vitamin A, D, and B12 from just a finger-prick in minutes—indicating a shift toward compact, multipurpose diagnostics useful in both clinics and homes. Artificial Intelligence–Enhanced Digital Nucleic Acid Amplification (dNAAT)Cutting-edge techniques such as digital PCR (dPCR) and digital LAMP (dLAMP), combined with AI-powered image analysis, are enhancing diagnostic precision and sensitivity. These advancements pave the way for scalable, faster, and more accurate molecular testing, even at the point of care. In Vitro Diagnostics Market Opportunity What is the Opportunity for the In Vitro Diagnostics Market? The growing prevalence of chronic diseases like cancer, diabetes, and cardiovascular diseases increases demand for in vitro diagnostics for early detection of diseases. The increasing patient demand for early detection of chronic diseases increases demand for IVD tests. The increasing demand for tracking the progression of chronic diseases increases the adoption of IVD for managing disease effectively and adjusting treatment plans. The increasing development of personalised treatment requires IVD technologies. The availability of point-of-care testing increases adoption of IVD for efficient management of chronic conditions. The increasing awareness of early disease detection and the increasing demand for regular health check-ups increase the adoption of IVD. The growing prevalence of chronic diseases creates an opportunity for the growth of the in vitro diagnostics market. In Vitro Diagnostics Market Challenges and Limitations and Challenges: Why High Development Cost Limitation for the In Vitro Diagnostics Market? Despite several benefits of in vitro diagnostics in various disease diagnoses, the high development cost restricts the market growth. Factors like the need for extensive clinical validation, the complex nature of IVD platforms, stricter regulation, high investment in R&D, and intensive clinical trials are responsible for high development costs. The need for high investment in personnel, equipment, and reagents directly affects the market. The complexity of IVD technologies and lengthy development cycles increases the production costs. The stricter regulations for the development of IVD tests require a high cost. The need for extensive compliance, documentation, and quality assurance requires a high cost. The requirement of specialized materials and precision manufacturing increases the production cost. The high development cost hampers the growth of the in vitro diagnostics market. Scope of the In Vitro Diagnostics Market Report Attributes Key Statistics Market Size in 2025 USD 104.10 Billion Market Size in 2030 USD 117.18 Billion Market Size in 2032 USD 124.66 Billion Market Size by 2034 USD 132.07 Billion Growth Rate 2025-2034 CAGR of 2.30% Base Year 2024 Forecast Period 2025 to 2034 Historical Data 2021 to 2023 Largest Regional Market (2024) North America – 42% revenue share Fastest Growing Regional Market Asia Pacific Segments Covered Product, Technology, Application and Regions Regions Covered North America, APAC, Europe, Latin America, MEAN, Rest of the World Key Players Covered Alere, Inc., Hoffmann-La Roche Ltd., Arkray,Beckman Coulter, Becton Disckinson, Bio-Rad laboratories, Danaher, Sysmex Corporation, Abbott Laboratories and other ➡️ Become a valued research partner with us ☎ How Big is the U.S. In Vitro Diagnostics (IVD) Market? According to Precedence Research, the U.S. in vitro diagnostics (IVD) market size was evaluated at USD 34.98 billion in 2024 and is expected to rise from USD 35.43 billion in 2025 to approximately USD 42.55 billion by 2034, at a CAGR of 2.20% from 2025 to 2034. The Complete Study is Immediately Accessible | Download the Sample Pages of this Report@ U.S. In Vitro Diagnostics Market Key Takeaways The U.S. in vitro diagnostics market reached USD 34.98 billion in 2024. It is projected to hit around USD 42.63 billion by 2034. The market is growing at a CAGR of 2% from 2025 to 2034. By product, the reagents segment held the highest share of 67% in 2024. By test location, the point-of-care segment dominated the market in 2024. By technology, the Immunoassay segment is expected to grow at a significant CAGR from 2025 to 2034. By application, the infectious diseases segment dominated the market with the biggest market share in 2024. By application, the oncology segment is expected to witness the fastest CAGR of growth during the forecast period of 2025-2034. By end user, the hospital segment held the dominating share of the market in 2024. U.S. In Vitro Diagnostics Market Leading Companies Alere, Inc. Beckman Coulter BD Bio-Rad laboratories Danaher Abbott Laboratories Thermo Fisher Scientific Inc. bioMérieux, Inc Quest Diagnostics Illumina, Inc. Get Immediate Access – Secure Your Copy of This Premium Research Report@ Which Region Dominated the In Vitro Diagnostics Market? North America dominated the in vitro diagnostics market in 2024. The well-established healthcare infrastructure, like research centers, modern clinical laboratories, and hospitals, increases the adoption of IVD. The ongoing technological innovations like digital health integration, high-throughput systems, and lab-on-a-chip equipment in IVD help the market growth. The increasing prevalence of infectious and chronic diseases increases the adoption of IVD. The increasing healthcare spending and focus on personalised medicine increase the adoption of IVD. The presence of major players like BD, Abbott, and Thermo Fisher Scientific drives the market growth. Why Asia Pacific Experiencing the Fastest Growth in the In Vitro Diagnostics Market? Asia Pacific is experiencing the fastest growth in the market during the forecast period. The growing prevalence of chronic diseases like cancer, diabetes, and cardiovascular diseases increases the adoption of IVD. The growing government investment in healthcare infrastructure and increasing spending on diagnostics increases demand for IVD, helping the market growth. The increasing awareness about the early detection of diseases and the growing expansion of healthcare facilities like clinics & hospitals increases adoption of IVD, supporting the overall growth of the market. 'The integration of AI with molecular diagnostics will reshape IVD workflows over the next decade, improving test turnaround times and accuracy, particularly in decentralized settings,' said Deepa Pandey, Principal Consultant at Precedence Research. In Vitro Diagnostics Market Segmentation Analysis: Product Analysis: Why did Reagent Segment Dominate the In Vitro Diagnostics Market? The reagent segment dominated the in vitro diagnostics market in 2024. The compatibility of reagents with various diagnostics platforms, like point-of-care, clinical laboratories, and hospitals, helps the market growth. The growth in personalised medicine increases the adoption of reagents. The growth in diagnostics like oncology, infectious diseases, and chronic diseases increases the adoption of reagents. The growing utilization of molecular diagnostic techniques increases demand for reagents, driving the overall growth of the market. The instruments segment is the fastest-growing in the market during the forecast period. The growing prevalence of chronic diseases like cardiovascular conditions, diabetes, and cancer increases demand for instruments for early detection. The increasing focus on early detection of diseases and timely treatment increases demand for instruments. The ongoing innovations in diagnostic technologies and the expansion of point-of-care testing support the market growth. Technology Analysis: How Immunoassay Segment Held the Largest Share in the In Vitro Diagnostics Market? The immunoassay segment held the largest revenue share in the in vitro diagnostics market in 2024. The increasing detection of various analytes like proteins, drugs, hormones, and antibodies increases the adoption of immunoassays. The increasing demand for ELISA and CLIA immunoassays helps the market growth. The increasing demand for POC testing and the increasing availability of central labs increase the adoption of immunoassays. The increasing risks of infectious diseases and chronic diseases increase demand for immunoassay-based diagnosis, driving the overall market growth. The molecular diagnostics segment is experiencing the fastest growth in the market during the forecast period. The growing utilization of techniques like next-generation sequencing & PCR for early disease diagnosis helps the market growth. The increased spread of infectious diseases increases the adoption of molecular diagnostics to control the spread of disease. The increasing development of personalised medicine and growth in at-home testing & point-of-care fuels demand for molecular diagnostics, supporting the overall market growth. Application Analysis: Which Application Segment Dominated the In Vitro Diagnostics Market? The oncology segment dominated the in vitro diagnostics market in 2024. The increasing prevalence of cancer increases demand for IVD for accurate diagnosis and early detection of conditions. The ongoing advancements in molecular diagnostics, like liquid biopsies and next-generation sequencing, help in the market growth. The increasing demand for early detection of cancer and the growth in the development of personalised medicines increases the demand for IVD. The increasing demand for IVD tests for various cancers like lung, prostate cancers, breast cancers, and colorectal drives the market growth. The infectious disease segment is the fastest-growing in the market during the forecast period. The growth in infectious diseases like viral outbreaks, respiratory infections, and STDs increases demand for IVD. The increasing awareness about the early detection of infectious diseases and focus on reducing transmission increases the adoption of IVD. The increasing prevalence of hepatitis, HIV, and tuberculosis increases demand for IVD, supporting the overall market growth. Test Location Analysis: How Point of Care Segment Held the Largest Share in the In Vitro Diagnostics Market? The point of care segment held the largest revenue share in the in vitro diagnostics market in 2024. The increasing demand for faster test results and focus on reducing turnaround times increases the adoption of point of care. The increasing need for IVD tests in underserved and remote areas increases the adoption of IVD. The focus on the management of chronic conditions like cardiovascular diseases and diabetes increases demand for POC. The increasing suitability of POC in various settings like doctors' offices, hospitals, and clinics drives the market growth. The home care segment is experiencing the fastest growth in the market during the forecast period. The growing patients' preference for testing at home and the growing expansion of home-based testing help the market growth. The increasing development of automated, user-friendly, and portable IVD devices increases adoption of care. The increasing management of chronic conditions like cardiovascular diseases & diabetes increases demand for home care, supporting the overall growth of the market. End User Analysis: Why did the Hospital Segment Dominate the In Vitro Diagnostics Market? The hospitals segment dominated the in vitro diagnostics market in 2024. The high availability of a wide range of diagnostic tests and the increasing number of patients increase the adoption of hospitals. The growing demand for accurate and early diagnosis of diseases increases the demand for hospitals. The availability of advanced technologies like molecular diagnostic tools, automated analyzers, and others helps the market growth. The presence of trained personnel, well-established infrastructure, and high-quality equipment in hospitals drives the market growth. Related Topics You May Find Useful: ➢ In-Vitro Inflammatory Bowel Disease Diagnostics Market: Uncover how biomarker innovations are transforming early IBD detection ➢ Infectious Disease In-Vitro Diagnostics Market: Explore rising demand for rapid pathogen testing and accuracy-driven diagnostics ➢ In-Vitro Diagnostics Enzymes Market: See how enzyme-based assays are becoming indispensable in chronic disease detection ➢ Diagnostic Testing Market: Track how expanding cardiology testing and hospital-led diagnostics are reshaping global healthcare ➢ Next-Generation IVD Market: Dive into how AI, genomics, and precision medicine are redefining diagnostic frontiers ➢ Cancer IVD Market: Analyze how early cancer detection and immunoassays are fueling a surge in diagnostic innovation ➢ Cancer Diagnostics Market: Discover how hospital-led screening and consumables-led solutions are doubling market size by 2034 ➢ DNA Diagnostics Market: Explore how PCR tech and oncology testing are powering DNA testing's rapid growth ➢ IVD Contract Manufacturing Market: Understand how outsourcing efficiencies and consumable demand are driving diagnostic scale-up ➢ In-Vitro Colorectal Cancer Screening Tests Market: Track rising demand for non-invasive CRC screening and lab-based diagnostics In Vitro Diagnostics Market Top Companies Alere, Inc. Hoffmann-La Roche Ltd. Arkray Beckman Coulter Becton Dickinson Bio-Rad Laboratories Danaher Sysmex Corporation Abbott Laboratories Recent Developments: In August 2024, InBios launched an in vitro diagnostic test, a serological ELISA kit for strongyloidiasis. The kit provides results under 75 minutes and is intended for use only in patients with symptoms, clinical history, and signs. (Source: In June 2023, GenWorks Health launched IVD tests for malaria & dengue. The test kits include iScreen Dengue NS1 and iScreen Malaria Card Antigen. The IVD products aim to diagnose, treat, prevent, and cure seasonal diseases. (Source: In September 2023, NeoDx Biotech launched an IVD kit, the HLA-B27 RT-PCR kit for detecting autoimmune disorders. The kits help to analyze disorders like psoriasis, reactive arthritis, ankylosing spondylitis, and inflammatory bowel syndrome. (Source: Case Study: AI-Powered Molecular Diagnostics at Sunrise Labs Boosts Cancer Detection Rates Sunrise Labs, a leading diagnostic center network in Southeast Asia, faced challenges in delivering early, accurate cancer diagnoses to patients in semi-urban and rural areas. Traditional lab workflows required samples to be shipped to centralized facilities, causing delays of 3–5 days before results reached clinicians. Solution Implemented: In 2023, Sunrise Labs partnered with a global IVD leader to deploy a portable, AI-enhanced molecular diagnostics platform capable of running PCR-based oncology tests on-site. The system integrated with the lab's electronic health record (EHR) system, enabling seamless data transfer and analysis. Key Innovations: Point-of-Care Molecular Testing: Allowed oncologists to receive results within 90 minutes. AI-Driven Image Analysis: Improved detection accuracy for early-stage cancers by 18% compared to conventional lab workflows. Custom Reagent Kits: Designed for tropical climates to maintain stability without cold-chain dependency. Results Achieved: Turnaround Time Reduced: From 3–5 days to under 2 hours. Screening Uptake Increased: 35% more patients underwent cancer screening in the first year. Cost Efficiency: Operational costs dropped by 22% due to reduced logistics and sample handling. Patient Outcomes: Early detection rates for breast and cervical cancer improved, enabling earlier treatment interventions. Industry Implication: This case underscores how integrating AI with IVD molecular diagnostics can dramatically improve accessibility and patient outcomes in emerging markets, aligning with broader industry trends toward decentralization and personalized medicine. It also highlights the commercial potential for IVD players to target underserved regions with tailored product designs. In Vitro Diagnostics Market Segments Covered in the Report By Product Reagents Instruments Services By Test Location Point of Care Home Care Others By Technology Immunoassay Instruments Reagents Services Hematology Instruments Reagents Services Clinical Chemistry Instruments Reagents Services Molecular Diagnostics Instruments Reagents Services Coagulation Instruments Reagents Services Microbiology Instruments Reagents Services Others Instruments Reagents Services By Application Diabetes Cardiology Nephrology Infectious Disease Oncology Drug Testing Autoimmune Diseases Others By End User Hospitals Standalone Laboratories Academic & Medical Schools Point-of-Care Others By Region North America U.S. Canada Europe Germany UK France Italy Spain Sweden Denmark Norway Asia Pacific China Japan India South Korea Thailand Latin America Brazil Mexico Argentina Middle East & Africa South Africa UAE Saudi Arabia Kuwait Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as Immediate Delivery Available | Buy This Premium Research Report@ You can place an order or ask any questions, please feel free to contact at sales@ | +1 804 441 9344 Stay Ahead with Precedence Research Subscriptions Unlock exclusive access to powerful market intelligence, real-time data, and forward-looking insights, tailored to your business. From trend tracking to competitive analysis, our subscription plans keep you informed, agile, and ahead of the curve. Browse Our Subscription Plans@ About Us Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. Web: Our Trusted Data Partners: Towards Healthcare | Towards Packaging | Towards Automotive | Towards Chem and Materials | Towards FnB | Towards Consumer Goods | Statifacts | Towards EV Solutions | Towards Dental | Nova One Advisor | Market Stats Insight Get Recent News: For the Latest Update Follow Us: LinkedIn | Medium | Facebook | Twitter ✚ Explore More Market Intelligence from Precedence Research: ➡️ In-Vitro Fertilization Market: Explore how technological advances and rising infertility treatments are driving global IVF demand ➡️ Artificial Intelligence Diagnostics Market: See how AI-powered tools are revolutionizing accuracy and speed in clinical diagnostics ➡️ Non-Invasive Cancer Diagnostics Market: Discover how liquid biopsies and imaging innovations are reshaping cancer detection ➡️ Home Diagnostics Market: Track how convenience and digital health integration are fueling at-home testing adoption ➡️ Point-of-Care Diagnostics Market: Understand how rapid testing solutions are transforming care delivery in clinics and beyond ➡️ Infectious Respiratory Disease Diagnostics Market: Analyze demand shifts driven by pandemic preparedness and respiratory health awareness ➡️ Breast Cancer Diagnostics Market: Learn how imaging, biopsy, and AI tools are advancing early breast cancer detection ➡️ Point-of-Care Molecular Diagnostics Market: Explore how portable PCR and molecular tools are enhancing real-time diagnosis ➡️ Rapid Diagnostics Market: See how speed, accuracy, and accessibility are redefining modern diagnostics ➡️ Next-Generation Cancer Diagnostics Market: Discover how genomic profiling and precision oncology are shaping next-gen cancer testing ➡️ Tissue Diagnostics Market: Understand how histopathology innovations are improving disease characterization ➡️ Blood Transfusion Diagnostics Market: Track advances in screening technologies ensuring safer transfusion practices ➡️ Infectious Disease Diagnostics Market: Explore how rising disease outbreaks are accelerating global diagnostic capabilities ➡️ Point-of-Care Infectious Disease Diagnostics Market: See how rapid and mobile solutions are revolutionizing infectious disease management ➡️ DNA Diagnostics Market: Learn how genetic testing is unlocking new frontiers in personalized medicine ➡️ Infectious Disease In-Vitro Diagnostics Market: Discover how innovation in IVD is boosting accuracy in pathogen detectionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
